Matthew Farabaugh
About Matthew Farabaugh
Matthew Farabaugh CFO Experience
Matthew Farabaugh serves as the Chief Financial Officer, bringing more than 19 years of expertise in finance and business. His extensive background covers significant areas like clinical and basic research in immunology, oncology, cell and gene therapy, and infectious diseases. Farabaugh’s role has involved substantial responsibilities and management within large-scale financial operations and strategic planning in the biotech sector.
Matthew Farabaugh Education and Finance Training
Matthew Farabaugh has a strong educational foundation with a Bachelor of Science degree in Microbiology from Duquesne University, followed by a Master of Science degree in Molecular Biotechnology from the University of Pennsylvania. He further enhanced his financial acumen through training at the Wharton School of Business, equipping him with advanced skills essential for his roles in finance and management.
Matthew Farabaugh Role at WuXi Advanced Therapies
Before his current role, Matthew Farabaugh was the Finance Manager at WuXi Advanced Therapies. In this position, he managed revenue and contract obligations for a $100 million US portfolio, focusing on research, manufacturing, and testing of cell and gene therapy products. His financial oversight was critical in advancing the company's objectives in these innovative therapeutic areas.
Matthew Farabaugh Contribution to UPENN-Novartis Global Program
Matthew Farabaugh played a significant role as a member of the UPENN-Novartis Global Program Team under the leadership of Dr. Carl June. He was responsible for managing a $50 million annual clinical development plan. This plan was key to obtaining FDA approval for the CAR T cell therapy Kymriah, which is designed to treat pediatric patients with relapsed acute lymphoblastic leukemia.